Meirong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meirong Li has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Allan Z. Zhao
Guangdong University of Technology
1 shared publication- Bangxu Sun
Central Laboratory of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People’s Hospital of Shenzhen, Shenzhen 518172, China
1 shared publication - Chengbin Yang
Shenzhen University Medical School
1 shared publication Fanghong Li
Guangdong University of Technology
1 shared publication- Jia Liu
Central Laboratory, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People’s Hospital of Shenzhen, 518172 Shenzhen, Guangdong, China
1 shared publication - Jingyu Yang
School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China
1 shared publication
Latest Publications
- Open Access
- 6 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 854
Multifunctional Mesoporous Silica-Coated Gold Nanorods Mediate Mild Photothermal Heating-Enhanced Gene/Immunotherapy for Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related deaths in the world. It is urgent to search for safe and effective therapies to address the CRC crisis. The siRNA-based RNA interference targeted silencing of PD-L1 has extensive potential in CRC treatment but is limited by the lack of efficient delivery vectors. In this work, the novel cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODNs)/siPD-L1 co-delivery vectors AuNRs@MS/CpG ODN@PEG-bPEI (ASCP) were successfully prepared by two-step surface modification of CpG ODNs-loading and polyethylene glycol-branched polyethyleneimine-coating around mesoporous silica-coated gold nanorods. ASCP promoted dendritic cells (DCs) maturation by delivering CpG ODNs, exhibiting excellent biosafety. Next, mild photothermal therapy (MPTT) mediated by ASCP killed tumor cells and released tumor-associated antigens, further promoting DC maturation. Furthermore, ASCP exhibited mild photothermal heating-enhanced performance as gene vectors, resulting in an increased PD-L1 gene silencing effect. Enhanced DCs maturity and enhanced PD-L1 gene silencing significantly promoted the anti-tumor immune response. Finally, the combination of MPTT and mild photothermal heating-enhanced gene/immunotherapy effectively killed MC38 cells, leading to strong inhibition of CRC. Overall, this work provided new insights into the design of mild photothermal/gene/immune synergies for tumor therapy and may contribute to translational nanomedicine for CRC treatment.
- 6 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 854
Open AccessMultifunctional Mesoporous Silica-Coated Gold Nanorods Mediate Mild Photothermal Heating-Enhanced Gene/Immunotherapy for Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related deaths in the world. It is urgent to search for safe and effective therapies to address the CRC crisis. The siRNA-based RNA interference targeted silencing of PD-L1 has extensive potential in CRC treatment but is limited by the lack of efficient delivery vectors. In this work, the novel cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODNs)/siPD-L1 co-delivery vectors AuNRs@MS/CpG ODN@PEG-bPEI (ASCP) were successfully prepared by two-step surface modification of CpG ODNs-loading and polyethylene glycol-branched polyethyleneimine-coating around mesoporous silica-coated gold nanorods. ASCP promoted dendritic cells (DCs) maturation by delivering CpG ODNs, exhibiting excellent biosafety. Next, mild photothermal therapy (MPTT) mediated by ASCP killed tumor cells and released tumor-associated antigens, further promoting DC maturation. Furthermore, ASCP exhibited mild photothermal heating-enhanced performance as gene vectors, resulting in an increased PD-L1 gene silencing effect. Enhanced DCs maturity and enhanced PD-L1 gene silencing significantly promoted the anti-tumor immune response. Finally, the combination of MPTT and mild photothermal heating-enhanced gene/immunotherapy effectively killed MC38 cells, leading to strong inhibition of CRC. Overall, this work provided new insights into the design of mild photothermal/gene/immune synergies for tumor therapy and may contribute to translational nanomedicine for CRC treatment.
- Open Access
- 7 April 2020
- Published by Springer Nature in Research Square
Inhibition of acute leukemia with attenuated Salmonella typhimurium strain VNP20009
Background Despite recent promising progress, the prognosis of acute leukemia (AL) patients remains to be improved. New therapies are therefore still needed. Spontaneous complete remission (SCR) of leukemia caused by severe bacterial infection in clinic suggests the possibility of bacterial treatment for AL. An engineered attenuated Salmonella typhimurium VNP20009 with good tolerance and safety has been shown to be highly effective as an anti-tumor agent in many solid cancer models, but it has not been applied in leukemia. Therefore, we selected VNP20009 as a candidate for the bacterial therapy of AL in this study. Methods Murine xenograft tumor models were used to verify the growth inhibition effect of VNP20009 on AL tumors. Histopathological features of the tumor were observed by H&E staining, Ki-67 immunohistochemical staining and TUNEL immunofluorescence staining. The apoptosis proteins Bax and cleaved caspase-3 in tumors were detected by Western blotting. The ratios of apoptosis, green fluorescent protein positive (GFP + ) cells and immune cells were detected by flow cytometry. Blood cell count were counted by IDEXX automatic five-classification blood cell analyzer. Detection of cytokines and chemokines in serum was completed on a Luminex Multi-factor Detection Platform. Results VNP20009 can induce apoptosis of AL cells by up-regulating the expression levels of Bax and cleaved caspase-3 . Furthermore, VNP20009 significantly inhibited the proliferation of MLL-AF9-induced AML cells and prolonged the survival of the AML-carrying mice. VNP20009 restored the counts of white blood cell and its five subsets in PB to near-physiological values, and elevated the levels of certain cytokines, such as tumor necrosis factor-α (TNF-α), leukemia inhibitory factor (LIF), interferon-γ (IFN-γ), chemokine C-X-C motif ligand-10 (CCXC-10) and C-C motif ligand-2 (CCL-2). Moreover, the ratio of immune cells, including natural killer cells (NKs), CD4 + Th1-type cells and CD8 + IFN-γ-producing effector T cells were highly upregulated in the AML mice treated with VNP20009. Conclusions VNP20009 induces the apoptosis of AL cells and activates the immune system, leading to the development of a strong and effective anti-tumor systemic response and tumor remission in acute leukemia. Keywords: acute leukemia, attenuated Salmonella typhimurium VNP20009, immunotherapy, bacterial cancer therapy, apoptosis
- 7 April 2020
- Published by Springer Nature in Research Square
Open AccessInhibition of acute leukemia with attenuated Salmonella typhimurium strain VNP20009
Background Despite recent promising progress, the prognosis of acute leukemia (AL) patients remains to be improved. New therapies are therefore still needed. Spontaneous complete remission (SCR) of leukemia caused by severe bacterial infection in clinic suggests the possibility of bacterial treatment for AL. An engineered attenuated Salmonella typhimurium VNP20009 with good tolerance and safety has been shown to be highly effective as an anti-tumor agent in many solid cancer models, but it has not been applied in leukemia. Therefore, we selected VNP20009 as a candidate for the bacterial therapy of AL in this study. Methods Murine xenograft tumor models were used to verify the growth inhibition effect of VNP20009 on AL tumors. Histopathological features of the tumor were observed by H&E staining, Ki-67 immunohistochemical staining and TUNEL immunofluorescence staining. The apoptosis proteins Bax and cleaved caspase-3 in tumors were detected by Western blotting. The ratios of apoptosis, green fluorescent protein positive (GFP + ) cells and immune cells were detected by flow cytometry. Blood cell count were counted by IDEXX automatic five-classification blood cell analyzer. Detection of cytokines and chemokines in serum was completed on a Luminex Multi-factor Detection Platform. Results VNP20009 can induce apoptosis of AL cells by up-regulating the expression levels of Bax and cleaved caspase-3 . Furthermore, VNP20009 significantly inhibited the proliferation of MLL-AF9-induced AML cells and prolonged the survival of the AML-carrying mice. VNP20009 restored the counts of white blood cell and its five subsets in PB to near-physiological values, and elevated the levels of certain cytokines, such as tumor necrosis factor-α (TNF-α), leukemia inhibitory factor (LIF), interferon-γ (IFN-γ), chemokine C-X-C motif ligand-10 (CCXC-10) and C-C motif ligand-2 (CCL-2). Moreover, the ratio of immune cells, including natural killer cells (NKs), CD4 + Th1-type cells and CD8 + IFN-γ-producing effector T cells were highly upregulated in the AML mice treated with VNP20009. Conclusions VNP20009 induces the apoptosis of AL cells and activates the immune system, leading to the development of a strong and effective anti-tumor systemic response and tumor remission in acute leukemia. Keywords: acute leukemia, attenuated Salmonella typhimurium VNP20009, immunotherapy, bacterial cancer therapy, apoptosis